Redeye provides a research update on Faron Pharmaceuticals following the outcome of the company’s recent share issue and clinical progress with lead candidate bexmarilimab. Bolstered by promising interim results from the BEXMAB study, we raise our LoA for bexmarilimab. Having adjusted for the share issue, we revise our valuation with an updated base case of EUR2 (5) per share.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/